Gross Profit Trends Compared: GSK plc vs Arrowhead Pharmaceuticals, Inc.

GSK vs Arrowhead: A Decade of Gross Profit Trends

__timestampArrowhead Pharmaceuticals, Inc.GSK plc
Wednesday, January 1, 201417500015683000000
Thursday, January 1, 201538200015070000000
Friday, January 1, 201615833318599000000
Sunday, January 1, 20173140770919844000000
Monday, January 1, 20181614232120580000000
Tuesday, January 1, 201916879557721891000000
Wednesday, January 1, 20208799206622395000000
Friday, January 1, 202113828700022511000000
Saturday, January 1, 202223281000019770000000
Sunday, January 1, 202324073500021763000000
Monday, January 1, 20243551000
Loading chart...

Cracking the code

Gross Profit Trends: GSK plc vs Arrowhead Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of GSK plc and Arrowhead Pharmaceuticals, Inc. from 2014 to 2023. GSK, a global healthcare giant, consistently reported robust profits, peaking in 2021 with a 43% increase from 2014. In contrast, Arrowhead Pharmaceuticals, a smaller biotech firm, demonstrated remarkable growth, with gross profits surging by over 137,000% from 2014 to 2023. This stark contrast highlights the dynamic nature of the industry, where established players maintain steady growth, while emerging companies can experience exponential increases. Notably, data for 2024 is incomplete, reflecting the unpredictable nature of financial forecasting. This comparison underscores the importance of strategic innovation and market adaptation in achieving financial success in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025